Core Viewpoint - A lawsuit has been filed against Iovance Biotherapeutics, Inc. and its senior executives for potential violations of federal securities laws, following disappointing financial results and issues with its melanoma treatment, Amtagvi [1][2][5]. Company Overview - Iovance Biotherapeutics is a commercial-stage biopharmaceutical company focused on developing treatments for melanoma and other solid tumor cancers [3]. Product Launch and Issues - Iovance launched its key melanoma treatment, Amtagvi, in February 2024, but has faced challenges with its authorized treatment centers (ATCs) [3]. - The company claimed that its ATCs would drive demand for Amtagvi; however, there were long timelines for patient treatment initiation and high patient drop-off rates due to ineffective patient identification and selection [4]. Financial Performance - On May 8, 2025, Iovance reported disappointing financial results for the first quarter of 2025 and revised its full-year 2025 revenue guidance downward, citing slow treatment timelines and high patient drop-off rates [5]. - Following the announcement of these results, Iovance's stock price fell over 44%, from $3.17 per share to $1.75 per share within a day [6].

Core Viewpoint - A class action lawsuit has been filed against Iovance Biotherapeutics, Inc. for allegedly misleading investors about its business prospects, particularly regarding the launch dynamics of its cell therapy product, Amtagvi [1][2]. Company Performance - Iovance reported a total product revenue of $49.3 million for Q1 2025, down from $73.7 million in the previous quarter, indicating a significant decline [3]. - The company revised its full fiscal year 2025 revenue guidance from a range of $450 million - $475 million to $250 million - $300 million, representing a reduction of over 40% at the midpoint [3]. - The updated revenue forecast reflects challenges with the growth trajectories and treatment timelines for new Authorized Treatment Centers (ATCs) [3]. Allegations and Investigation - The lawsuit alleges that Iovance failed to disclose critical issues, including longer timelines for new ATCs to begin treating patients, inefficiencies in patient identification and selection, and the resulting higher costs and lower revenues [2]. - The complaint claims that these undisclosed factors rendered the company's positive statements about its business and prospects materially misleading [2]. Legal Proceedings - Shareholders interested in participating as lead plaintiffs in the class action must file their papers by July 14, 2025 [4]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4].

Core Viewpoint - A class action securities lawsuit has been filed against Iovance Biotherapeutics, Inc. due to alleged securities fraud that negatively impacted investors between May 9, 2024, and May 8, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Iovance provided misleading positive statements while concealing material adverse facts about its growth potential, specifically its inability to generate demand for its treatments [2]. - On July 25, 2024, Iovance announced a reduction in its revenue guidance for fiscal year 2024, attributing this to maintenance issues, lower-than-expected Proleukin sales, and the variable pace of treatment initiation at approved centers [2]. - Following the announcement, Iovance's stock price plummeted from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025, marking a decline of approximately 44.8% in one day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified period have until July 14, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing significant settlements for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA). Shareholders who purchased shares of IOVA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/iovance-biotherapeutics-inc-loss-submission-form/?id=150533&from=3 CL ...

NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and consumer rights litigation firm, alerts investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ: IOVA), and certain of its former and current officers and/or directors (collectively, “Defendants”). The Class Action asserts clai ...

SAN FRANCISCO, May 29, 2025 (GLOBE NEWSWIRE) -- A year ago, Bay Area biotech firm Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) was riding high on the promise of its newly approved cell therapy, Amtagvi. Today, the mood has shifted dramatically. On May 16, 2025, UBS analysts reportedly slashed their rating on Iovance shares from Buy to Neutral and issued a stark price target cut—from $17 to just $2—citing mounting concerns over the drug’s commercial rollout and the company’s ability to meet market expectatio ...

NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Iovance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/iovance-biotherapeutics-inc-class-action-lawsuit. Investors have until July 14, 20 ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Iovance Biotherapeutics, Inc. regarding a class action lawsuit due to alleged misleading statements and failure to disclose material adverse facts about the company's growth potential [1] Summary by Relevant Sections Allegations - The complaint alleges that during the class period from May 9, 2024, to May 8, 2025, Iovance provided overly positive statements while concealing significant issues regarding its ability to meet demand for its treatments [1] - Key factors leading to the company's reduced revenue guidance included maintenance of the iCTC, lower than expected Proleukin sales, and the variable pace of treatment initiation at approved centers [1] Financial Impact - Following the announcement of reduced revenue guidance on July 25, 2024, Iovance's stock price plummeted from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025, marking a decline of approximately 44.795% in just one day [1] Next Steps for Shareholders - Shareholders who purchased IOVA shares during the specified class period are encouraged to register for the class action by July 14, 2025, to potentially become lead plaintiffs [2] - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle [2] Firm's Commitment - The Gross Law Firm aims to protect investors' rights and ensure companies adhere to responsible business practices, seeking recovery for losses incurred due to misleading statements [3]

Core Viewpoint - Iovance Biotherapeutics, Inc. is facing a securities class action lawsuit due to alleged failure to disclose material information during the specified class period, leading to significant financial losses for investors [3]. Group 1: Lawsuit Details - Investors who purchased Iovance securities between May 9, 2024, and May 8, 2025, have until July 15, 2025, to file lead plaintiff applications [1]. - The lawsuit is pending in the United States District Court for the Northern District of California, under the case name Farberov v. Iovance Biotherapeutics, Inc., et al., Case No. 25-cv-4199 [5]. Group 2: Financial Performance - Iovance reported a total product revenue of $49.3 million for Q1 2025, a decline from $73.7 million in the previous quarter [4]. - The company has revised its full fiscal year 2025 total product revenue guidance from a range of $450 million - $475 million to $250 million - $300 million, reflecting recent launch dynamics [4]. - Following the announcement of these financial results, Iovance's share price fell by 44.8%, from $1.42 to $1.75 per share on May 9, 2025, with unusually heavy trading volume [4]. Group 3: Legal Representation - Kahn Swick & Foti, LLC, a prominent securities litigation law firm, is representing investors in this case, with a history of recovering investment losses due to corporate fraud [5].

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who purchased Iovance Biotherapeutics, Inc. securities between May 9, 2024, and May 8, 2025, alleging that the company misled investors regarding its business prospects [1][2]. Company Performance - Iovance Biotherapeutics reported a total product revenue of $49.3 million for Q1 2025, a significant decline from $73.7 million in the previous quarter [3]. - The company revised its full fiscal year 2025 total product revenue guidance from $450 million - $475 million to $250 million - $300 million, indicating a reduction of over 40% at the midpoint [3]. - The updated revenue forecast reflects challenges with the launch dynamics of Amtagvi and the growth trajectories of Authorized Treatment Centers (ATCs) [3]. Allegations and Issues - The lawsuit claims that Iovance failed to disclose several critical issues, including: 1. New ATCs faced longer timelines to begin treating patients with Amtagvi [2]. 2. Ineffectiveness of the sales team and ATCs in patient identification and selection, leading to higher patient drop-offs [2]. 3. These dynamics resulted in higher costs and lower revenue due to ATCs not keeping pace with manufactured products [2]. 4. Positive statements made by the company regarding its business and prospects were materially misleading [2]. Legal Proceedings - Shareholders interested in serving as lead plaintiffs in the class action must file their papers with the court by July 14, 2025 [4]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4].